Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab

Kurebayashi, Junichi; Kanomata, Naoki; Yamashita, Tetsumasa; Shimo, Toshiro; Mizutoh, Akiko; Moriya, Takuya; Sonoo, Hiroshi

doi:10.1007/s12282-013-0478-y

Cited by 15 publications

(12 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…von Minckwitz et al (9) and Gwak et al (10) reported four molecular outcomes in detail following surgery. Patients with HER2-amplified or hormone receptor-negative may have an additional benefit from neoadjuvant therapy to achieve pCR, which suggests that patients with different HER2 or hormone receptor status have different sensitivity for neoadjuvant therapy, although there were poor prognostic factors (22). The similar association between molecularly and pCR has been reported previously.…”

Section: Heterogeneity Effect Size ----------------------------------supporting

confidence: 71%

Efficacy of vinorelbine-based neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis of randomized controlled trials

Gao

Wei

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

The present study aimed to compare the effects of vinorelbine-based neoadjuvant chemotherapy and vinorelbine-free regimens. A meta-analysis of all the relevant randomized controlled trials was performed to investigate the improvement in pathological complete response (pCR), overall response rate (ORR) and breast-conserving surgery (BCS). The PubMed and Embase databases were searched for relevant studies reporting randomized controlled trials comparing vinorelbine-based neoadjuvant chemotherapy with vinorelbine-free regimens until July 2013. Risk ratios/odds ratio and 95% confidence intervals (CIs) were used to estimate the association between vinorelbine in neoadjuvant chemotherapy and various efficacy outcomes. Fixed-or random-effect models were adopted to pool the data. Five eligible studies with a total of 1,495 patients were included in the meta-analysis. Compared to vinorelbine-free chemotherapy, vinorelbine-based regimens demonstrated no significant improvement in clinical outcomes including: pCR [relative risk (RR)=1.016; 95% CI, 0.738-1.399; P=0.922], ORR (RR=1.048; 95% CI, 0.969-1.133; P=0.239) and BCS (RR=1.764; 95% CI, 0.734-4.239; P=0.205). However, vinorelbine-based regimens were associated with a lower incidence of grade 3-4 alopecia (OR, 0.617; 95% CI, 0.448-0.848; P=0.003). In a hierarchical analysis for patients who received neoadjuvant chemotherapy, the proportion of subjects achieving pCR was significantly increased when HER2-amplified (RR=2.31; 95% CI, 1.20-4.43; P=0.01) and hormone receptor negative (RR=0.488; 95% CI, 0.263-0.908; P=0.023). The present review confirms that neoadjuvant chemotherapy vinorelbine-based regimens are unlikely to emerge as superior to pCR, ORR and BCS. Hierarchical analysis indicated that the HER2-amplified and hormone receptor-negative patients were significantly associated with a pathological response rate.

show abstract

Section: Heterogeneity Effect Size ----------------------------------supporting

confidence: 71%

Efficacy of vinorelbine-based neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis of randomized controlled trials

Gao

Wei

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Bauer ve arkadaşları (14) çalışmasında triple negatif grupta ortanca tümör çapını 22 mm, Japonya'daki çalışmada ise Her2 pozitif grupta ortanca tümör çapı 21 mm saptanmıştır (13). Çalışmamızda da iki gruptaki hastaların ortanca tümör çapı 25 mm civarında bulunmuştur.…”

Section: Tartışma Ve Sonuçlarunclassified

Survival Analysis of Triple Negative and Her2 Positive Breast Cancer Patients: Single Center Report

Varol¹,

Çakar²,

Yıldız³

et al. 2014

J Breasth Health

View full text Add to dashboard Cite

Objective: Triple negative and human epidermal growth factor receptor 2 (Her2) positive breast tumors are characterized by the absence of expression of estrogen and progesterone receptors and with either Her2 expression or not. Generally, they are larger tumors with higher grade, higher incidence of recurrence and distant metastasis. This article will investigate clinical, pathological, and molecular features of these high risk breast cancer patients and whether these features are correlated with recurrences or not. Materials and Methods:Breast cancer patients of 109 triple negative and 81 Her2 positive histology followed in the medical oncology department of our hospital between 2004 and 2011 were enrolled in the study. These patients were mostly treated with adjuvant and neoadjuvant chemotherapy. Results:The median age of patients was 51 and 52 years. Median follow-up duration was 22 and 29 months. Four patients in each group died during the follow-up. 5 year survival rates were 81.1% in triple negative group and 73.5% in Her2 positive group. Relapses were seen in 30 patients. Bone and brain were the most common metastatic sites in the first and second groups respectively. Triple negative patients having larger tumor size and Her2 positive patients having positive lymph node or not treated with radiotherapy have a statistically higher chance of relapse during the follow-up. Conclusion:Despite the short median follow-up time, approximately one sixth of our patients had recurrence and this supported the aggressive course of the disease in high risk patients. For this reason, risk factors that help us to predict the early recurrences in both of the groups are very important.Key words: Breast cancer, survival analysis, retrospective studies, recurrences ÖZET Amaç: Triple negatif ve insan epidermal büyüme faktör reseptörü 2 (Her2) pozitif meme tümörleri, östrojen ve progesteron reseptörlerinin negatif olması ve HER-2 ekspresyonun olup olmaması ile karakterizedir. Diğer meme kanserleri ile karşılaştırıldığında daha büyük ve daha yüksek dereceli tümörlerdir, erken nüks ve metastaz sıklığı daha fazladır. Bu yazıda yüksek riskli meme kanserlerinin klinik, patolojik ve moleküler özellikleri ve bu özelliklerin nüks ile ilişkisi araştırılacaktır. Sonuç: Kısa izlem süresine rağmen hastalarımızın yaklaşık altıda birinde nüks gözlenmesi, bu yüksek riskli hastalardaki agresif seyri desteklemektedir. Dolayısıyla her iki hasta grubunda da, hastalık nüksünü erken dönemde öngörülebilecek risk faktörlerinin saptanması önem taşımaktadır.Anahtar sözcükler: Meme kanseri, sağkalım analizi, retrospektif çalışmalar, nüks GirişMeme kanseri kadınlarda görülen kanserlerin en sık görülen türü olup yaklaşık %25-%30`unu oluşturmaktadır. Kansere bağlı mortalite (%18) ise akciğer kanserlerinden sonra ikinci sırada yer almaktadır (1). Meme kanseri 30 yaşından önce nadir görülmekle birlikte bu yaşı takip eden reprodüktif yıllarda hızlı bir artış gösterir. Bu artış menopoz sonrasında da yavaş eğimle yükselmeye devam eder (2).Son dönemlerde...

show abstract

“…Trastuzumab, used as the first‐line treatment for HER2‐positive metastatic breast cancer, is a fully humanized version of a murine HER2‐targeted IgG1 monoclonal antibody with a molecular mass of 148 400 Da . Since it was first approved by FDA in 1998, trastuzumab has achieved great clinical success and saved thousands of lives of breast cancer patients.…”

Section: Targeted Biopharmaceuticals For Breast Cancer Treatmentmentioning

confidence: 99%

Cell‐specific biomarkers and targeted biopharmaceuticals for breast cancer treatment

Liu

Yang

et al. 2016

Cell Proliferation

View full text Add to dashboard Cite

Breast cancer is the second leading cause of cancer death among women, and its related treatment has been attracting significant attention over the past decades. Among the various treatments, targeted therapy has shown great promise as a precision treatment, by binding to cancer cell-specific biomarkers. So far, great achievements have been made in targeted therapy of breast cancer. In this review, we first discuss cell-specific biomarkers, which are not only useful for classification of breast cancer subtyping but also can be utilized as goals for targeted therapy. Then, the innovative and generic-targeted biopharmaceuticals for breast cancer, including monoclonal antibodies, non-antibody proteins and small molecule drugs, are reviewed. Finally, we provide our outlook on future developments of biopharmaceuticals, and provide solutions to problems in this field.

show abstract

Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab

Cited by 15 publications

References 43 publications

Efficacy of vinorelbine-based neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis of randomized controlled trials

Efficacy of vinorelbine-based neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis of randomized controlled trials

Survival Analysis of Triple Negative and Her2 Positive Breast Cancer Patients: Single Center Report

Cell‐specific biomarkers and targeted biopharmaceuticals for breast cancer treatment

Contact Info

Product

Resources

About